{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T10:30:59Z","timestamp":1786357859235,"version":"build-2736575974"},"reference-count":53,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T00:00:00Z","timestamp":1786233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Fondazione per le Attivit\u00e0 di Ricerca in Oncologia of Pontedera (FARO), Pisa, Italy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Cyclin-Dependent Kinase 4\/6 inhibitors (CDK 4\/6i) represented a paradigm shift in the treatment of patients with metastatic hormone-receptor-positive (HR+), HER2-negative (HER2-) breast cancer patients. When disease progression occurs and further hormonal manipulations or target therapies fail, chemotherapy remains a therapeutic choice. For these reasons, resources should be invested in redesigning the best treatment strategy with the current chemotherapy drugs available. Nevertheless, the preferred strategy typically remains a planned sequence of single chemotherapeutic agents. This approach endeavors to extend overall survival and maintain quality of life. Within this complex and evolving therapeutic scenario, where the necessity for effective and treatment options is crucial, we explore in the present paper a perspective for a hypothetical new role of bevacizumab combined with paclitaxel for patients with metastatic HR+, HER2- breast cancer patients resistant to hormone therapy. Recent findings from our preliminary published pharmacogenetic studies, could suggest the efficacy of bevacizumab as linked to a well-defined genomic profile of genes implicated in the process of neoangiogenesis (e.g., favorable profile: VEGF-A rs833061\/VEGFR-2 rs1870377: CT\/AT, CT\/AA, TT\/AA, TT\/TT, CC\/TT), concluding the present perspective underlying the fact that bevacizumab combined with paclitaxel will be reconsidered with this new potential use only if well-designed prospective trials confirm what has been observed from our retrospective data.<\/jats:p>","DOI":"10.3390\/jcm15166172","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T09:24:53Z","timestamp":1786353893000},"page":"6172","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Perspective on a Possible New Role for Bevacizumab Combined with Paclitaxel in Hormone-Resistant Metastatic Breast-Cancer Patients"],"prefix":"10.3390","volume":"15","author":[{"given":"Giacomo","family":"Allegrini","sequence":"first","affiliation":[{"name":"Department of Oncology, Azienda USL Toscana Nord Ovest, 56121 Pisa, Italy"},{"name":"Division of Medical Oncology, Livorno Hospital, Azienda USL Toscana Nord Ovest, 57124 Livorno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Acconci","sequence":"additional","affiliation":[{"name":"Department of Oncology, Azienda USL Toscana Nord Ovest, 56121 Pisa, Italy"},{"name":"Division of Medical Oncology, Livorno Hospital, Azienda USL Toscana Nord Ovest, 57124 Livorno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianna","family":"Musettini","sequence":"additional","affiliation":[{"name":"Department of Oncology, Azienda USL Toscana Nord Ovest, 56121 Pisa, Italy"},{"name":"Division of Medical Oncology, Livorno Hospital, Azienda USL Toscana Nord Ovest, 57124 Livorno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5268-5107","authenticated-orcid":false,"given":"Luigi","family":"Coltelli","sequence":"additional","affiliation":[{"name":"Department of Oncology, Azienda USL Toscana Nord Ovest, 56121 Pisa, Italy"},{"name":"Division of Medical Oncology, Pontedera Hospital, Azienda USL Toscana Nord Ovest, 56025 Pontedera, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Finale","sequence":"additional","affiliation":[{"name":"Department of Oncology, Azienda USL Toscana Nord Ovest, 56121 Pisa, Italy"},{"name":"Division of Medical Oncology, Livorno Hospital, Azienda USL Toscana Nord Ovest, 57124 Livorno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samanta","family":"Cupini","sequence":"additional","affiliation":[{"name":"Department of Oncology, Azienda USL Toscana Nord Ovest, 56121 Pisa, Italy"},{"name":"Division of Medical Oncology, Livorno Hospital, Azienda USL Toscana Nord Ovest, 57124 Livorno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Bartalini","sequence":"additional","affiliation":[{"name":"Department of Oncology, Azienda USL Toscana Nord Ovest, 56121 Pisa, Italy"},{"name":"Division of Medical Oncology, Livorno Hospital, Azienda USL Toscana Nord Ovest, 57124 Livorno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Orlandi","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7120-9141","authenticated-orcid":false,"given":"Guido","family":"Bocci","sequence":"additional","affiliation":[{"name":"Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Freihat, O., Sipos, D., and Kovacs, A. (2025). Global burden and projections of breast cancer incidence and mortality to 2050: A comprehensive analysis of GLOBOCAN data. Front. Public Health, 13.","DOI":"10.3389\/fpubh.2025.1622954"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and Letrozole in Advanced Breast Cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.annonc.2024.04.013","article-title":"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3","volume":"35","author":"Goetz","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): A randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/jnci\/djaa071","article-title":"Overall Survival of CDK4\/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis","volume":"112","author":"Schettini","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.23.00137","article-title":"Overall Survival with Palbociclib Plus Letrozole in Advanced Breast Cancer","volume":"42","author":"Slamon","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1158\/1078-0432.CCR-21-3032","article-title":"Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+\/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial","volume":"28","author":"Lu","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib Combined with Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","article-title":"Imlunestrant with or without Abemaciclib in Advanced Breast Cancer","volume":"392","author":"Jhaveri","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer","volume":"391","author":"Turner","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in Hormone Receptor\u2013Positive Advanced Breast Cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejca.2023.01.031","article-title":"OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"184","author":"Robson","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","article-title":"Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: Final overall survival results from the EMBRACA trial","volume":"31","author":"Litton","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_19","unstructured":"U.S. Food and Drug Administration (FDA) (FDA News Release, 2010). FDA approves Halaven for late-stage breast cancer [press release], FDA News Release."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"DESTINY-Breast06 Trial Investigators. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1200\/JCO.22.01002","article-title":"Sacituzumab Govitecan in Hormone Receptor-Positive\/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer","volume":"40","author":"Rugo","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e473372","DOI":"10.1200\/EDBK-25-473372","article-title":"After a CDK4\/6 Inhibitor: State of the Art in Hormone Receptor\u2013Positive Metastatic Breast Cancer","volume":"45","author":"Teysir","year":"2025","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Pathak, N., Mittal, A., Kumar, S., Nagpal, C., Amir, E., Haldar, P., Gangadharaiah, B.B., Kumar, A., Mishra, A., and Batra, A. (2025). Systematic Review and Network Meta-Analysis on Treating Hormone Receptor-Positive Metastatic Breast Cancer After CDK4\/6 Inhibitors. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32010053"},{"key":"ref_26","unstructured":"National Comprehensive Cancer Network (2026). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae), Breast Cancer, National Comprehensive Cancer Network. Version 1.2026."},{"key":"ref_27","first-page":"CD008792","article-title":"Combination versus sequential single agent chemotherapy for metastatic breast cancer","volume":"13","author":"Dear","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/s41580-023-00631-w","article-title":"Biology and therapeutic targeting of vascular endothelial growth factor A","volume":"24","author":"Ferrara","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_29","unstructured":"U.S. Food and Drug Administration (FDA) (2008). FDA Grants Accelerated Approval for Avastin for Previously Untreated Metastatic HER2-Negative Breast Cancer."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3816\/CBC.2003.n.007","article-title":"E2100: A phase III trial of paclitaxel versus paclitaxel\/bevacizumab for metastatic breast cancer","volume":"3","author":"Miller","year":"2003","journal-title":"Clin. Breast Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus Bevacizumab for Metastatic Breast Cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","article-title":"RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer","volume":"29","author":"Robert","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/bjc.2013.69","article-title":"Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer","volume":"108","author":"Miles","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_34","unstructured":"U.S. Food and Drug Administration (FDA) (2011). Final Decision on Withdrawal of Breast Cancer Indication for Avastin (Bevacizumab) Following Public Hearing."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/jnci\/djp369","article-title":"Detecting an overall survival benefit that is derived from progression-free survival","volume":"101","author":"Broglio","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_36","unstructured":"European Medicines Agency (EMA) (2010). European Medicines Agency Confirms Positive Benefit-Risk Balance for Avastin in Combination with Paclitaxel, EMA. Report No.: EMA\/CHMP\/830232\/2010."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1158\/1078-0432.CCR-12-3409","article-title":"Predictive biomarkers for bevacizumab: Are we there yet?","volume":"19","author":"Maru","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1200\/JCO.2008.16.1612","article-title":"Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100","volume":"26","author":"Schneider","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1200\/JCO.2012.46.2762","article-title":"Markers of response for the antiangiogenic agent bevacizumab","volume":"31","author":"Lambrechts","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Wu, D., Pan, C., Hu, Y., Shi, Z., Zhou, Y., and Xiao, M. (2024). A bibliometric and visualization analysis of research trends and hotspots on targeted therapy for breast cancer from 2003 to 2022. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1366900"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Li, M., Liu, W., and Wu, S.N. (2022). Using Machine Learning Methods to Predict Bone Metastases and Individualized Survival Outcomes in Breast Infiltrating Ductal Carcinoma Patients. Front. Public Health, 10.","DOI":"10.3389\/fpubh.2022.922510"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"586","DOI":"10.21147\/j.issn.1000-9604.2019.04.03","article-title":"An update on biomarkers of potential benefit with bevacizumab in breast cancer","volume":"31","author":"Liang","year":"2019","journal-title":"Chin. J. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejca.2016.09.024","article-title":"Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation","volume":"70","author":"Miles","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S1470-2045(14)70439-5","article-title":"Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): An open-label, randomised phase 3 trial","volume":"15","author":"Puglisi","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_46","first-page":"30","article-title":"Multifactor dimensionality reduction strategy for detecting gene-gene interactions in case-control studies of complex diseases","volume":"1","author":"Moore","year":"2002","journal-title":"Appl. Bioinform."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/annonc\/mdq572","article-title":"Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer","volume":"22","author":"Pander","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Chitoran, E., Rotaru, V., Stefan, D.C., Gullo, G., and Simion, L. (2025). Blocking Tumoral Angiogenesis VEGF\/VEGFR Pathway: Bevacizumab-20 Years of Therapeutic Success and Controversy. Cancers, 17.","DOI":"10.3390\/cancers17071126"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/978-1-62703-447-0_22","article-title":"Epistasis, complexity, and multifactor dimensionality reduction","volume":"1019","author":"Pan","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.2217\/pgs.14.140","article-title":"Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab","volume":"15","author":"Allegrini","year":"2014","journal-title":"Pharmacogenomics"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41523-022-00400-6","article-title":"A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients","volume":"8","author":"Coltelli","year":"2022","journal-title":"npj Breast Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"13","DOI":"10.32604\/or.2026.073799","article-title":"Bevacizumab and Paclitaxel in Advanced, Hormone Receptor-Positive Breast Cancer: Multifactor Dimensionality Reduction Methodology to Identify Best Overall Survival","volume":"34","author":"Coltelli","year":"2026","journal-title":"Oncol. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1200\/OP.20.00903","article-title":"Universal Pretreatment DPYD Genotyping in Fluoropyrimidine Candidates: Still Controversial but with Clear Instructions for Practitioners, at Last!","volume":"16","author":"Cremolini","year":"2020","journal-title":"JCO Oncol. Pract."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/16\/6172\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T09:50:15Z","timestamp":1786355415000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/16\/6172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,9]]},"references-count":53,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["jcm15166172"],"URL":"https:\/\/doi.org\/10.3390\/jcm15166172","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,9]]}}}